XFOR — X4 Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $317.27m
- $186.06m
- $35.11m
X4 Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Closes $115 Mln Loan Facility With Hercules Capital
X4 Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Files For Offering Of Up To 42.8 Mln Shares Offered By Selling Stockholders
X4 Pharma gains as immune disease drug meets main goal in late-stage study
Brief: X4 Pharmaceuticals Announces Positive Phase 3 Results For Mavorixafor
U.S. STOCKS ON THE MOVE-Applied Digital, Amdocs, First Watch
U.S. STOCKS ON THE MOVE-Shake Shack, Western Alliance, Blue Apron
X4 Pharmaceuticals rises on $65 mln private investment
Brief: X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-The-Market
Brief: X4 Pharmaceuticals Inc Says Believes Has Sufficient Funds To Support Operations Into Q2 Of 2024
X4 Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: X4 Pharma Announces Abstract Of Phase 3 Data To be Presented At 2023 Annual Meeting Of The Clinical Immunology Society
X4 Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: X4 Pharmaceuticals Reports Fourth-Quarter And Full-Year 2022 Financial Results
X4 Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Inc - As Of December 31, 2022, Co Had Approximately 2.5% Of Its Cash Deposits With Svb
Brief: X4 Pharmaceuticals’Presentations At ASH 2022 Highlight Opportunity For Its Neutropenia Drug
U.S. RESEARCH ROUNDUP- Accenture, Box, Vail Resorts